A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome.
Fármaco: MBG453, NIS793, canakinumab en monoterapia o en combinación
Fase: Ib
SMD riesgo bajo/Intermedio, con <10% blastos y citopenias sintomáticas. No entran SMD/NMPc (LMMC), nitherapy related.
María Diez Campelo (mdiezcampelo@usal.es)
Hospital Universitario de Salamanca